Copper in Alzheimer's disease: too much or too little?

Authors: Quinn, Joseph F; Crane, Susanne; Harris, Christopher; Wadsworth, Teri L

Source: Expert Review of Neurotherapeutics, Volume 9, Number 5, May 2009 , pp. 631-637(7)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

A considerable amount of literature has accrued examining the role of copper in the pathogenesis of Alzheimer's disease. Remarkably, there is in vitro and animal data to support both copper toxicity and copper deficiency as relevant mechanisms in Alzheimer's disease. These data have prompted preliminary clinical trials of both copper complexing therapy and copper supplementation therapy, which have yielded mixed results. The preclinical and clinical studies are discussed here in an effort to determine how to move forward with rational clinical trials focused on copper modulation.

Keywords: Alzheimer's disease; animal model; chelation; clinical trial; copper; oxidative damage

Document Type: Research article

DOI: http://dx.doi.org/10.1586/ern.09.27

Affiliations: 1: Oregon Health and Science University/Portland VA Medical Center, Department of Neurology CR-131, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA., Email: quinnj@ohsu.edu

Publication date: 2009-05-01

More about this publication?

Expert Review of Neurotherapeutics provides expert commentary on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer's and Parkinson's.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites